Investing.com - Gain Therapeutics (NASDAQ: GANX) reported first quarter EPS of $-0.220, $0.10 better than the analyst estimate of $-0.319. Revenue for the quarter came in at $60K versus the consensus estimate of $133.33K.
Gain Therapeutics's stock price closed at $2.42. It is down -49.790% in the last 3 months and down -52.850% in the last 12 months.
Gain Therapeutics saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Gain Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Gain Therapeutics's Financial Health score is "weak performance".
Check out Gain Therapeutics's recent earnings performance, and Gain Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar